Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 1/20 | 0.37 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.34 |
| ▸ | CCNC | P24863 | 1/20 | 0.34 |
| ▸ | CDK8 | P49336 | 1/20 | 0.34 |
| ▸ | CCNK | O75909 | 4/20 | 0.33 |
| ▸ | CDK12 | Q9NYV4 | 4/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 4/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.33 |
| ▸ | LTA4H | P09960 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.31 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.31 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.31 |
| ▸ | PDE2A | O00408 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21241336 | 0.77 | HPGD (0.34) | HPGDSNOTUMLTA4HBRD4HPGD | |
| SCHEMBL13602061 | 0.77 | CCR1 (0.46) | CYP11B1CYP11B2CHRNA7 | |
| SCHEMBL9263374 | 0.77 | NOTUM (0.53) | HPGDSNOTUMLTA4HBRD4HPGD | |
| SCHEMBL13114689 | 0.77 | CCR1 (0.56) | HPGDSCCNCCDK8CCNKCDK12 | |
| SCHEMBL14211174 | 0.77 | HPGDS (0.43) | HPGDSNOTUMLTA4HBRD4 | |
| SCHEMBL12896119 | 0.76 | LTA4H (0.40) | HPGDSNOTUMCCNCCDK8CCNK | |
| SCHEMBL12248374 | 0.74 | HPGDS (0.34) | HPGDSLTA4HHPGD | |
| SCHEMBL14988353 | 0.73 | HPGDS (0.40) | HPGDSCCNCCDK8CCNKCDK12 | |
| SCHEMBL1558150 | 0.73 | CA2 (0.40) | HPGDSCCNCCDK8CCNKCDK12 | |
| SCHEMBL31255994 | 0.73 | HPGDS (0.40) | HPGDSCCNCCDK8LTA4HBRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230128041-A1 | PARP1 INHIBITORS AND USES THEREOF | XINTHERA, INC. | 2023-04-27 | — | — | US | disclosed |
| US-20230128041-A1 | PARP1 INHIBITORS AND USES THEREOF | XINTHERA, INC. | 2023-04-27 | — | — | US | disclosed |
| US-7378418-B2 | Azabicyclic heterocycles as cannabinoid receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230128041-A1 | PARP1 INHIBITORS AND USES THEREOF | PARP1, PARP11, PARP12 | HPGDS 1272/4885NOTUM 3876/4885CCNC 2218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.